Advertisements
Setipiprant 866460-33-5
| Price: | US$ 1 / Unit |
|---|---|
| Minimum Order: | 10 |
| Payment Terms: | Western Union, Money Gram, Bank Transfer, Bitcoin, |
| Port of Export: | shenzhen |
Product Details
| Model No.: | 866460-33-5 | Brand Name: | RAWSGEAR |
|---|
| Certification: | COA.HPLC.ISO9009 |
|---|---|
| Specification: |
Setipiprant (ACT-129,968, KYTH-105) is a drug acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application. |
Packaging & Delivery
| Packaging: | Foil bag and Disguised bag |
|---|---|
| Delivery/Lead Time: | 3-5 work days |
| Production Capacity: | 1000kg/month |
Product Description
Setipiprant (ACT-129,968, KYTH-105) is a drug acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application. Web: *
Web: *
Email: *
Skype: +8615711952876
Whatsapp +8615711952876
|
SUPPLIER PROFILE
|
|||
|---|---|---|---|
| Company: | Wuhan Shuiyixing Chemical Co., Ltd. | ||
| City/State | Wuhan, hubei | Country: |
China 
|
| Business Type: | Export - Manufacturer / Trading Company | Established: | NA |
| Member Since: | 2019 | Contact Person | Gayle Lee |
SUPPLIER PROFILE
City/State/Country -
Wuhan, hubei
China
Business Type -
Export - Manufacturer / Trading Company
Established -
NA
Member Since -
2019
Contact Person -
Gayle Lee